Speech treatment improves dysarthria in multisystemic ataxia: a rater-blinded, controlled pilot-study in ARSACS

Redenlab partnered with investigators in Australia and Germany to conduct dysarthria treatment trial in ataxia published in Journal of Neurology

Abstract: We aimed to provide proof-of-principle evidence that intensive home-based speech treatment can improve dysarthria in complex multisystemic degenerative ataxias, exemplified by autosomal recessive spastic ataxia Charlevoix-Saguenay (ARSACS). Feasibility and piloting efficacy of speech training specifically tailored to cerebellar dysarthria was examined through a 4-week program in seven patients with rater-blinded assessment of intelligibility (primary outcome) and naturalness and acoustic measures of speech (secondary outcomes) performed 4 weeks before, immediately prior to, and directly after training (intraindividual control design). Speech intelligibility and naturalness improved post treatment. This provides piloting evidence that ataxia-tailored speech treatment might be effective in degenerative cerebellar disease.

See here for study details

Related Post

  • Posted on 17 October, 2021
    Redenlab’s latest iOS application provides state of the art audio capture, storage and analysis of speech and language data for...
    • Posted on 27 September, 2021
      Redenlab extend their reach in the #speech neuroscience and clinical trials by adding #leaders at the forefront of #digitalhealth &...
      • Posted on 12 March, 2021
        Hardware selection is an important and often overlooked component of speech research. All data are acquired using a microphone and...